Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode the science, funding outlook, and trial milestones inside MAIA Biotechnology’s SEC paperwork can be overwhelming. If you’ve ever typed “MAIA Biotechnology insider trading Form 4 transactions” or “MAIA Biotechnology quarterly earnings report 10-Q filing,” you know the raw documents rarely answer questions quickly. Oncology pipeline updates, dilution risks, and cash runway figures are scattered across hundreds of pages and multiple form types.
Stock Titan solves that challenge in one view. Our AI reviews every submission to EDGAR the moment it appears, converting dense language into concise insights. Whether you need “MAIA Biotechnology Form 4 insider transactions real-time” alerts that flag executive buys and sells, or a dashboard of “MAIA Biotechnology SEC filings explained simply,” our platform delivers context that matters. Looking for fast “MAIA Biotechnology earnings report filing analysis” without wading through footnotes? AI summaries pair the latest 10-Q numbers with historical trends so you can spot changes in R&D spend or cash burn instantly.
- Save hours understanding MAIA Biotechnology SEC documents with AI.
- Monitor MAIA Biotechnology executive stock transactions Form 4 before material announcements.
- Read the MAIA Biotechnology annual report 10-K simplified for pipeline risks and patent positions.
- Compare pay packages via the MAIA Biotechnology proxy statement executive compensation.
- Stay informed with MAIA Biotechnology 8-K material events explained whenever trial data or financing news breaks.
From insider trades to clinical readouts, every filing arrives with plain-English explanations, real-time updates, and exportable data—giving biotech investors the clarity they need to act decisively.
MAIA Biotechnology reported a material financing-related disclosure. The Board approved director participation in a Private Placement to align director and stockholder interests. A director, Stan Smith, executed a Purchase Agreement to subscribe for 19,230 shares of common stock at $1.30 per share for an aggregate of approximately $25,000 and received warrants to purchase up to 19,230 shares exercisable at $1.57 beginning six months after issuance with a three-year term. The Director Shares and Director Warrants are being issued under the Company’s 2021 Equity Incentive Plan as an Unrestricted Stock Award and an Award of Options. Separately, the company amended certain common stock purchase warrants originally issued February 24, 2025 to reduce the exercise price from $1.87 to $1.30 for warrants to purchase 1,396,667 shares, including amendments affecting FGMK Holdings LLC for warrants to purchase 1,350,000 shares. Several related forms and a press release are filed as exhibits.
MAIA Biotechnology reported that the European Patent Office has decided to grant a patent that broadly covers a portfolio of ateganosine-based analogues directed to telomere-targeting anticancer therapy. The patent also covers methods of using ateganosine (THIO) either alone or prior to administration of checkpoint inhibitors (CPIs). The filing attaches a press release as Exhibit 99.1 which is incorporated by reference.
The filing contains the Companys standard forward-looking statements cautioning that future results are subject to risks and uncertainties, including the initiation, timing, cost, progress and results of preclinical and clinical studies, regulatory filings and approvals, manufacturing and commercialization, market acceptance, and intellectual property protection. No financial results or transaction terms are disclosed in this report.
MAIA Biotechnology, Inc. reported unaudited condensed consolidated results for the quarter ended June 30, 2025. The company held $10,144,522 in cash and reported total assets of $11,045,854 and total liabilities of $7,169,170, leaving stockholders' equity of $3,876,684. The company had 31,818,480 shares issued and outstanding at June 30, 2025 and 32,993,220 shares outstanding as of August 11, 2025.
Operating expenses for the quarter were $5.17 million (R&D $3.11M; G&A $2.06M). Net loss was $5.35 million in the quarter and $9.86 million for the six months, narrower than the prior-year six-month loss of $16.95M; basic and diluted loss per share was $0.34 for the six months. Net cash used in operating activities for six months was $8.34 million; net cash provided by financing activities was $8.87 million from ATM sales and multiple private placements.
The filing discloses substantial doubt about the company’s ability to continue as a going concern within one year, noting an accumulated deficit of $97,099,055 and that additional equity or debt financing will be required.
FAQ
What is the current stock price of MAIA Biotechnology (MAIA)?
What is the market cap of MAIA Biotechnology (MAIA)?
